Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
02 February 2017 - 8:05AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome
editing company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, announced that Chief
Executive Officer and Founder Nessan Bermingham, Ph.D., will
present at the Leerink Partners 6th Annual Global Healthcare
Conference, Wednesday, February 15, 2017.
Details of the presentation are as follows:
Date: Wednesday, February 15, 2017 Location: Lotte New York
Palace, New York, New YorkTime: The presentation will be at 10:00
am ETWebcast: Available live during the presentation, and through
replay on the company’s website immediately following. To
participate in the webcast go to Leerink registration.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Intellia Contacts:
Media:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 857-706-1071
jenn.smoter@intelliatx.com
Investors:
John Graziano
Trout Group
+ 1 646-378-2942
jgraziano@troutgroup.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024